Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer
Riichiroh Maruyama(Shikoku Cancer Center), Masahiro Fukuoka(National Institute of Standards and Technology), Keisuke Tomii(Shikoku Cancer Center), Akira Inoue(Tohoku University Hospital), Masahiro Tsuboi(National Cancer Center Hospital East), Fumio Imamura(Osaka International Cancer Institute), Tetsu Shinkai(Shikoku Cancer Center), Y. Itoh(AstraZeneca (Japan)), Haiyi Jiang(AstraZeneca (Japan)), Kazuhiko Nakagawa(Dana-Farber Cancer Institute), Tomohide Tamura(Shikoku Cancer Center), Yutaka Nishiwaki(National Cancer Center Hospital East), Kenji Eguchi(Shikoku Cancer Center), Shunichi Negoro(Shikoku Cancer Center), Noriyuki Masuda(Shikoku Cancer Center), Yukito Ichinose(National Hospital Organization Kyushu Cancer Center), Nagahiro Saijo(National Cancer Center Hospital East), Koji Takeda(Shikoku Cancer Center), Masao Harada(Shikoku Cancer Center), Nobuyuki Yamamoto(Wakayama Medical University)
Cited by 365
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k